These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 9348407)
1. Neurochemical correlates of parkinsonism. Role of dopaminergic lesions. Hirsch EC; Herrero MT Adv Neurol; 1997; 74():119-26. PubMed ID: 9348407 [No Abstract] [Full Text] [Related]
2. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. Lopez-Real A; Rey P; Soto-Otero R; Mendez-Alvarez E; Labandeira-Garcia JL J Neurosci Res; 2005 Sep; 81(6):865-73. PubMed ID: 16015598 [TBL] [Abstract][Full Text] [Related]
3. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Kim JH; Auerbach JM; Rodríguez-Gómez JA; Velasco I; Gavin D; Lumelsky N; Lee SH; Nguyen J; Sánchez-Pernaute R; Bankiewicz K; McKay R Nature; 2002 Jul; 418(6893):50-6. PubMed ID: 12077607 [TBL] [Abstract][Full Text] [Related]
4. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Lee DY; Oh YJ; Jin BK Glia; 2005 Aug; 51(2):98-110. PubMed ID: 15789435 [TBL] [Abstract][Full Text] [Related]
5. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Smith PD; O'Hare MJ; Park DS Trends Mol Med; 2004 Sep; 10(9):445-51. PubMed ID: 15350897 [No Abstract] [Full Text] [Related]
6. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497 [TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease? Michel PP; Ruberg M; Hirsch E Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033 [TBL] [Abstract][Full Text] [Related]
8. Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Moses D; Drago J; Teper Y; Gantois I; Finkelstein DI; Horne MK Neuroscience; 2008 Jun; 154(2):606-20. PubMed ID: 18472226 [TBL] [Abstract][Full Text] [Related]
10. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393 [TBL] [Abstract][Full Text] [Related]
11. Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease. Jensen P; Pedersen EG; Zimmer J; Widmer HR; Meyer M Brain Res; 2008 Jul; 1218():13-20. PubMed ID: 18513704 [TBL] [Abstract][Full Text] [Related]
12. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: a new genetic model for Parkinson's disease? Le Pen G; Sonnier L; Hartmann A; Bizot JC; Trovero F; Krebs MO; Prochiantz A Parkinsonism Relat Disord; 2008; 14 Suppl 2():S107-11. PubMed ID: 18585951 [TBL] [Abstract][Full Text] [Related]
13. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. Okuno T; Nakatsuji Y; Kumanogoh A; Moriya M; Ichinose H; Sumi H; Fujimura H; Kikutani H; Sakoda S J Neurosci Res; 2005 Sep; 81(6):874-82. PubMed ID: 16041799 [TBL] [Abstract][Full Text] [Related]
14. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Smith Y; Villalba R Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of the midbrain dopamine system: Implications for Parkinson disease. Hassan A; Benarroch EE Neurology; 2015 Nov; 85(20):1795-805. PubMed ID: 26475693 [No Abstract] [Full Text] [Related]
16. Pallidal control of substantia nigra dopaminergic neuron firing pattern and its relation to extracellular neostriatal dopamine levels. Lee CR; Abercrombie ED; Tepper JM Neuroscience; 2004; 129(2):481-9. PubMed ID: 15501605 [TBL] [Abstract][Full Text] [Related]
17. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Liang CL; Wang TT; Luby-Phelps K; German DC Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972 [TBL] [Abstract][Full Text] [Related]
18. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Chu Y; Kordower JH Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279 [TBL] [Abstract][Full Text] [Related]
19. Iron metabolism and Parkinson's disease. Hirsch EC; Faucheux BA Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717 [TBL] [Abstract][Full Text] [Related]
20. Dopamine cell death by a single genetic mechanism: phenotypic analysis and linkage study of autosomal recessive juvenile parkinsonism. Matsumine H; Saito M; Ishikawa A; Yokochi M; Yamamura Y; Tsuji S; Mizuno Y Adv Neurol; 1999; 80():187-94. PubMed ID: 10410720 [No Abstract] [Full Text] [Related] [Next] [New Search]